Performance evaluation shows accurate antigen detection in HCV patients, indicating potential for public health improvements.
Key Points
Elecsys HCV Duo immunoassay demonstrated 63% detection of active infection in viraemic patients, improving diagnostic capabilities.
With a viral load of over 7 log IU/mL, the antigen detection rate reached 100%, highlighting its effectiveness in determining HCV status.
The study confirmed that 49% of new patients would require viral load testing to assess the need for treatment in a public healthcare setting.
Detection rates for genotype-1 infections were significantly higher at 69.6%, indicating the immunoassay's targeted efficiency in specific populations.